Deliverable Preview
What You'll Receive
Every engagement produces specific, presentation-ready deliverables. Here's what they look like, using a fictional gene therapy company as an example.
The samples below are based on a fictional company, NovaBio Therapeutics, a Series A gene therapy company developing an AAV9-based therapy for a rare neuromuscular disease. All content is illustrative. Actual deliverables are tailored to your specific program, modality, and stage.
Status Color System — Used Across All Deliverables
Exceeds
Strong, GO, Advance, Complete. No action needed.
Meets
Aligned, On Track. Progressing as expected.
Below Target
Revise, Watch, Needs Work, Gap. Action needed.
Critical
Critical, Pause, Blocked, Missing. Immediate action.
Document Category Headers
Study Design Review
5-7 business days
An independent protocol review before you commit budget to a CRO study. You receive specific recommendations with rationale, not vague feedback.
- Annotated protocol with specific recommendations
- Model selection assessment with rationale
- Endpoint and biomarker recommendations
- Statistical approach review
- Regulatory alignment notes
Study Design Review: NovaBio Therapeutics | AAV9-CAPN3 Efficacy Study
Protocol Assessment Summary
LGMD2A mouse appropriate
Molecular only — add functional
Extend 4 wk → 12 wk for durability
N=10/group adequate
Add serum biomarker panel
IV consistent with clinical plan
Critical Recommendation
Extend primary endpoint assessment from 4 weeks to 12 weeks to capture durability data. Add functional endpoints (grip strength, rotarod) alongside CAPN3 protein expression.
Also included in this package
Animal Model Selection Rationale
Rationale: best-characterized disease model with validated functional endpoints...
Endpoint & Biomarker Recommendations
Primary Endpoints
CAPN3 protein (Western blot) + grip strength (functional)
Secondary Endpoints
Rotarod, histopathology (fiber size), serum CK levels
Exploratory Biomarkers
Vector genome copies, anti-AAV9 antibodies, T-cell response
Regulatory Alignment Assessment
Strategy Diagnostic: NovaBio Therapeutics | AAV9-CAPN3 Program
Preclinical Readiness Assessment
Prioritized Next Steps
- Redesign efficacy study with functional endpoints
- Develop biomarker qualification strategy
- Initiate biodistribution pilot before GLP
Strategy Diagnostic
1-2 weeks
A multidimensional assessment tailored to your situation. Covers preclinical readiness, portfolio prioritization, diligence readiness, or all three. You walk away knowing exactly which studies to run next and in what order.
- Multidimensional readiness assessment with scores
- Prioritized study plan with sequencing
- Visual timeline with milestones
- Budget table with quarterly capital requirements
- Risk summary with mitigations
- Executive summary for board use
Also included in this package
Milestone Timeline with Decision Gates
Full visual with quarterly milestones, go/no-go gates, and dependencies...
Quarterly Capital Requirements
Risk Register with Mitigations
Each risk includes likelihood, mitigation plan, and monitoring triggers...
Preclinical Roadmap
A study-by-study plan from your current state through IND-enabling. Includes Pre-IND strategy and nonclinical regulatory writing when your program reaches that stage.
IND-Enabling Preclinical Roadmap: NovaBio Therapeutics
$1.28M
Total Nonclinical
Q2 2027
Projected IND
3 CROs
Recommended
2-4 weeks
- Study-by-study plan with sequencing and dependencies
- Visual roadmap with milestones and decision gates
- CRO shortlists with RFP scope drafts
- Budget with quarterly capital requirements
- Biomarker and translational strategy
- Risk assessment with mitigation plans
- Regulatory designation assessment
Also included in this package
CRO Recommendations & RFP Scopes
GLP Tox CROs
3 qualified CROs with capability matrices, pricing ranges, and draft RFP scope
BioDist CROs
2 recommended, specialized in AAV vector analysis
Program Risk Register
Translational Biomarker Strategy
Pharmacodynamic
CAPN3 protein, grip strength, rotarod
Safety
Anti-AAV9 Abs, liver enzymes, complement
Translational
Serum CK, vector genomes, T-cell assay
Designation Assessment
Portfolio Assessment: NovaBio Therapeutics | 3-Program Review
Program Comparison Heat Map
| Dimension | AAV9-CAPN3 | siRNA-NASH | mAb-CNS |
|---|---|---|---|
| Scientific Rationale | Strong | On Track | Gap |
| Competitive Position | Strong | Needs Work | Critical |
| Dev. Feasibility | On Track | On Track | Gap |
| Commercial Potential | On Track | Strong | On Track |
| Recommendation | ADVANCE | WATCH | PAUSE |
Recommended Budget Allocation
Concentrate on AAV9-CAPN3 (lead program with strongest competitive position). Maintain siRNA-NASH at POC level. Defer mAb-CNS until lead reaches IND-enabling.
Portfolio Assessment
2-4 weeks
A detailed assessment of each program with head-to-head comparison, prioritization recommendation, and a next-study plan for every program in your pipeline.
- Per-program multidimensional assessment
- Head-to-head comparison matrix with scores
- Prioritization recommendation with rationale
- Next-study plan per program
- Portfolio budget and timeline
- Board narrative with strategic positioning
Also included in this package
Per-Program Assessment: AAV9-CAPN3
Full assessment repeated for each program in the portfolio...
Portfolio Strategy — Board Summary
Strategic Positioning
Three-program portfolio with lead gene therapy asset targeting orphan indication with favorable competitive dynamics...
Investment Thesis
Concentrated resources on highest-probability program. Clear value inflection at efficacy readout Q2 2026.
Multi-Program Timeline & Budget
Diligence Readiness Package
2-4 weeks
Prepare your preclinical story for investors and partners. Find the gaps in the narrative, not just the data, and close them before the diligence call comes.
- Readiness scorecard across key dimensions
- Gap analysis with prioritized action plan
- TPP assessment and alignment review
- 35+ question Q&A guide with suggested responses
- Data room organization checklist
- Mock diligence sessions
- Investor/pharma profile matching
Diligence Readiness: NovaBio Therapeutics | Investor Preparation
Readiness Dashboard
Sample Q&A Entry (from 35+ guide)
“What is your dose rationale and how does it translate to the clinic?”
Lead with the NOAEL from tox study, bridge to allometric scaling, address therapeutic window relative to efficacious dose in animal model...
Also included in this package
35+ Diligence Q&A Responses
“What is your dose rationale?”
Lead with NOAEL, bridge to allometric scaling, address therapeutic window...
“How does your model predict human?”
Reference validation data, cite published translational correlation...
Data Room Organization Checklist
Target Product Profile Alignment
Investor/Pharma Profile Matching
Tier 1 Targets (3)
Rare disease-focused VCs with gene therapy portfolio
Tier 2 Targets (5)
Broad biotech VCs with neuromuscular interest
Pharma BD (2)
Active in gene therapy with rare disease pipeline gaps
NovaBio Therapeutics | AAV9-CAPN3 for LGMD2A
GO
WITH CONDITIONS
Stage: Series A
Modality: AAV Gene Therapy
Indication: LGMD2A (Rare)
Risk Matrix
CMC Scalability
CDMOs identified
Durability Risk
Extended study needed
Immunogenicity
Pre-screen protocol
Sarepta Entrant
Differentiation data
Management Questions
- What is the re-dosing strategy if efficacy wanes?
- How does dose-response compare to competitor data?
- What is the CMC timeline to clinical-grade material?
Buy-Side Diligence
48 hours - 4 weeks
Independent preclinical assessment for VCs and pharma BD teams. Every memo opens with a clear go/watch/pass recommendation. No hedging, no consultant-speak.
- Executive summary with go/watch/pass recommendation
- Mechanism and target assessment
- Translational feasibility and data quality review
- Competitive positioning analysis
- Risk register ranked by severity and likelihood
- Key questions for management diligence calls
Also included in this package
Competitive Positioning Assessment
Full landscape with differentiation analysis per competitor...
Mechanism & Translational Feasibility
Preclinical Data Quality Review
Advisory
Monthly or bi-weekly
Ongoing strategic guidance for teams navigating preclinical decisions in real time. Protocol reviews, strategy calls, and quarterly program reviews.
- Protocol and study report review with written comments
- Regular strategy calls (monthly or bi-weekly)
- Email access for time-sensitive questions
- Quarterly program review documents
Q1 2026 Program Review: NovaBio Therapeutics
Milestone Timeline
This Quarter's Recommendations
- Revise biodistribution pilot to include CNS tissues
- Begin GLP tox CRO evaluation (3 candidates identified)
- Schedule Pre-IND meeting for Q3
Also included in this package
Study Report Review — Written Comments
Comment #1
Section 4.2: Primary endpoint should include functional readout alongside molecular. Recommend adding grip strength per FDA precedent in DMD programs.
Comment #2
Section 6.1: N=8/group may be underpowered for this model. Suggest N=10 based on published variability data (Smith et al., 2024).
Strategy Call Summary & Action Items
March 15, 2026 — Bi-weekly Call
Monthly Operating Report: NovaBio | February 2026
Week 4 interim read
Monthly review call completed
RFP sent to 3 CROs
Pre-IND timing review
Q1 update drafted
2 new risks added
52% burned — on track for quarterly allocation
Decisions Needed from Leadership
- Approve GLP tox CRO selection (budget: $420K)
- Confirm Pre-IND meeting target date
- Review updated risk register (2 new items)
Fractional Head of Preclinical Strategy
Ongoing
Embedded senior leadership for your preclinical program. You get a VP-level preclinical strategist without the 6-month recruiting cycle or full-time cost.
- Monthly operating reports with status and action items
- CRO oversight and study design input
- Board materials and investor update support
- Risk register management and escalation
- CEO/CSO strategy sessions
- Nonclinical regulatory writing
- Vendor relationship management
Also included in this package
Q1 2026 Board Update Deck
Slide preview:
1. Program status dashboard
2. Key milestones achieved
3. Budget vs. actuals
4. Risk register update
5. Strategic recommendations
Active Risk Register — February 2026
Vendor Performance Scorecard
IND Module 2.4 Draft Section
Nonclinical Overview
2.4.1 Pharmacology: CAPN3 restoration in the LGMD2A mouse model demonstrated dose-dependent efficacy with ≥40% protein restoration at the target dose...
Draft for internal review. Aligned with FDA gene therapy IND guidance (2020).
These samples are illustrative. Every engagement is tailored to your specific program, modality, therapeutic area, and stage. Actual deliverables reflect the depth and specificity of your situation.
Want to see a deliverable closer to your program? Book a Strategy Call and we can walk through relevant examples.
Ready to See What This Looks Like for Your Program?
Book a Strategy Call. Complimentary, 30 minutes, no obligation. We'll discuss your situation and recommend the right engagement.
Book a Strategy Call30-minute call · No obligation · Confidential
info@bridgelinetranslational.com · bridgelinetranslational.com